Better conversations about immunotherapy, at every appointment.
Give oncologists, nurse specialists and MDTs an explainable second view of likely benefit and risk, built into the systems they already use.
Where Cure-IO shows up in the pathway.
Demographics, staging, ECOG and labs read from the record.
Side-by-side estimates for each candidate regimen.
Plain-language summary for the patient and family.
Higher irAE risk flags closer review.
Results feed local audit and calibration checks.
Fits the consultation, not the other way round.
Cure-IO opens inside the patient record with the fields already filled. Clinicians review, adjust and share the result, and every view is logged.
EHR integration
SMART on FHIR launch, HL7 v2 feeds, or CSV upload for pilots.
Patient summaries
Plain-English summaries with icon arrays, ready to print or send.
Security
SSO with SAML or OIDC, role-based access and full audit logs.
Clinical safety
DCB0129 hazard log, with support for your DCB0160 work.
What this estimate means for you
Out of 100 people with a similar profile treated with pembrolizumab and chemotherapy, about 47 would be expected to see their cancer shrink.
About 14 in 100 would have a serious side effect that needs treatment. Your care team will watch for these closely.
Bring explainable immunotherapy predictions to your team.
Book a 30-minute walkthrough for your clinical, data or pharma team, or start free in the Sandbox.